AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9337184 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hirulog (0.125 mg/kg bolus followed by 0.25 mg x kg(‐1) x h(‐1) for 12 hours then 0.125 mg x kg(‐1) x h(‐1))
Number of subjects: 412
Study 9337184 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose hirulog (0.25 mg/kg bolus followed by 0.5 mg x kg(‐1) x h(‐1) for 12 hours then 0.25 mg x kg(‐1) x h(‐1))
Number of subjects: 412
Study 9337184 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 412
Study 9337184 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hirulog
Number of subjects: 412
Study 9337184 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose hirulog
Number of subjects: 412
Study 8437833 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser treatment
Number of subjects: 19
Study 8437833 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 19
Study 3466935 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam alone
Number of subjects: 24
Study 3466935 — intervention group
Group type: COMPARATOR
Intervention: Diazepam alone
Number of subjects: 24
Study 3466935 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam + Fentanyl
Number of subjects: 24
Study 3466935 — intervention group
Group type: COMPARATOR
Intervention: Diazepam + Fentanyl
Number of subjects: 24
Study 30374692 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 µg IV CRH
Number of subjects: 120
Study 30374692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 26296327 — intervention group
Group type: EXPERIMENTAL
Intervention: PVCi-CMP group (96 patients)
Number of subjects: 168
Study 26296327 — intervention group
Group type: COMPARATOR
Intervention: Control group (72 patients)
Number of subjects: 168
Study 26296327 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 168
Study 24378745 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐amphetamine (0.3 mg/kg, p.o.)
Number of subjects: 33
Study 24378745 — intervention group
Group type: COMPARATOR
Intervention: lactose placebo
Number of subjects: 33
Study 23141813 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 145 70 mg every 2 weeks
Number of subjects: 631
Study 23141813 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 145 105 mg every 2 weeks
Number of subjects: 631
Study 23141813 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 145 140 mg every 2 weeks
Number of subjects: 631
Study 23141813 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 145 280 mg every 4 weeks
Number of subjects: 631
Study 23141813 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 145 350 mg every 4 weeks
Number of subjects: 631
Study 23141813 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 145 420 mg every 4 weeks
Number of subjects: 631
Study 23141813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 631
Study 19952829 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (4 kcal·kg(‐1)·wk(‐1)) for 6 months
Number of subjects: 464
Study 19952829 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (8 kcal·kg(‐1)·wk(‐1)) for 6 months
Number of subjects: 464
Study 19952829 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (12 kcal·kg(‐1)·wk(‐1)) for 6 months
Number of subjects: 464
Study 19952829 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control
Number of subjects: 464
Study 18082224 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical bacillus Calmette-Guerin
Number of subjects: 38
Study 18082224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 17238812 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 73
Study 17238812 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%
Number of subjects: 73
Study 17238812 — intervention group
Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 73
Study 15122555 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing a treatment simulation before surgery
Number of subjects: 184
Study 15122555 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who overestimated discomfort
Number of subjects: 184
Study 15122555 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychologically distressed patients before surgery
Number of subjects: 184
Study 15122555 — intervention group
Group type: COMPARATOR
Intervention: Standard presurgical consultation without treatment simulation
Number of subjects: 184
Study 11476123 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (10 mg for first two injections; 5 mg for third injection)
Number of subjects: 201
Study 11476123 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg for first two injections; 1 mg for third injection)
Number of subjects: 201
Study 11476123 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo for first two injections; olanzapine 10 mg for third injection)
Number of subjects: 201
Study 9550531 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute spinal cord injury
Number of subjects: 100
Study 7840527 — intervention group
Group type: EXPERIMENTAL
Intervention: CAV-E (cyclophosphamide 1000 mg/m2, adriamycin 50 mg/m2, vincristine 2 mg, plus etoposide 100 mg/m2)
Number of subjects: 75
Study 7840527 — intervention group
Group type: COMPARATOR
Intervention: CAV-T (teniposide 60 mg/m2 on days 2, 3, 4)
Number of subjects: 75
Study 7840527 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-interferon (3 x 10(6) I.U., i.m. daily x 9 months)
Number of subjects: 75
Study 7840527 — intervention group
Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 75
Study 7840527 — intervention group
Group type: EXPERIMENTAL
Intervention: CAV-E and CAV-T
Number of subjects: 75
Study 7840527 — intervention group
Group type: EXPERIMENTAL
Intervention: CAV-E
Number of subjects: 75
Study 7840527 — intervention group
Group type: COMPARATOR
Intervention: CAV-T
Number of subjects: 75
Study 3295323 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime (CFIX) 100 mg b.i.d.
Number of subjects: 252
Study 3295323 — intervention group
Group type: COMPARATOR
Intervention: Cefroxadine (CXD) 250 mg t.i.d.
Number of subjects: 252
Study 28741624 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive (30 μg ethinyl estradiol/0.15 mg levonorgestrel)
Number of subjects: 35
Study 28741624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 27565187 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncompetitive exergames with extrinsically framed health messages
Number of subjects: 595
Study 27565187 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive exergames with intrinsically framed health messages
Number of subjects: 595
Study 27565187 — intervention group
Group type: COMPARATOR
Intervention: Adolescents
Number of subjects: 595
Study 26341047 — intervention group
Group type: EXPERIMENTAL
Intervention: Proficiency-Based Progression (PBP) training plus simulator (group C)
Number of subjects: 44
Study 26341047 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator training (group B)
Number of subjects: 44
Study 26341047 — intervention group
Group type: COMPARATOR
Intervention: Traditional training (group A) (control)
Number of subjects: 44
Study 26341047 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of groups for achieving proficiency benchmark
Number of subjects: 44
Study 25947930 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg sublingual melatonin
Number of subjects: 61
Study 25947930 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg sublingual melatonin
Number of subjects: 61
Study 25947930 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg sublingual melatonin
Number of subjects: 61
Study 25947930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 21038019 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt‐FP 400 µg
Number of subjects: 20
Study 18478468 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy adjacent to inferior mesenteric artery root (Group D(3))
Number of subjects: 260
Study 18478468 — intervention group
Group type: COMPARATOR
Intervention: No lymphadenectomy adjacent to inferior mesenteric artery root (Group D(2))
Number of subjects: 260
Study 16575041 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction catheter (SC) guided technique
Number of subjects: 243
Study 16575041 — intervention group
Group type: COMPARATOR
Intervention: Digital technique
Number of subjects: 243
Study 12883897 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary exercise (alternate flexion-extensions of both lower legs with a weight of about 2.5% of body mass) for 20 seconds (brief voluntary exercise)
Number of subjects: 14
Study 12883897 — intervention group
Group type: COMPARATOR
Intervention: Passive movement (without weights, performed by experimenters pulling ropes attached to the subjects' ankles) for 20 seconds (brief passive movement)
Number of subjects: 14
Study 12883897 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary exercise for 3 minutes (long voluntary exercise)
Number of subjects: 14
Study 10714758 — intervention group
Group type: EXPERIMENTAL
Intervention: Premixed insulin therapy via pen-injector (Novopen II)
Number of subjects: 20
Study 10714758 — intervention group
Group type: COMPARATOR
Intervention: Patient-mixed insulin therapy via conventional syringe
Number of subjects: 20
Study 8957600 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with hypertensive heart disease
Number of subjects: 15
Study 8957600 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 15
Study 8234642 — intervention group
Group type: EXPERIMENTAL
Intervention: Nightguard vital bleaching (overnight insertion of mouthguard at bedtime)
Number of subjects: 0
Study 8234642 — intervention group
Group type: EXPERIMENTAL
Intervention: Nightguard vital bleaching (3-hour exposure with replenishment of test solution hourly)
Number of subjects: 0
Study 8234642 — intervention group
Group type: COMPARATOR
Intervention: Control solution (glycerin)
Number of subjects: 0
Study 3513425 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical 0.5% aminocaproic acid
Number of subjects: 0
Study 3513425 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride irrigation
Number of subjects: 0
Study 29641362 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine patch (175 mg) applied to umbilical trocar site
Number of subjects: 40
Study 29641362 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lidocaine patch)
Number of subjects: 40
Study 27095126 — intervention group
Group type: EXPERIMENTAL
Intervention: Video laryngoscopy (VL)
Number of subjects: 140
Study 27095126 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy (DL)
Number of subjects: 140
Study 24261547 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centred music therapy (FCMT) for 16 weeks in addition to early intervention programmes
Number of subjects: 23
Study 24261547 — intervention group
Group type: COMPARATOR
Intervention: Early intervention programme only
Number of subjects: 23
Study 22373758 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady competitive work
Number of subjects: 187
Study 22373758 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady noncompetitive work
Number of subjects: 187
Study 22373758 — intervention group
Group type: EXPERIMENTAL
Intervention: Working clients (steady competitive and noncompetitive)
Number of subjects: 187
Study 22373758 — intervention group
Group type: COMPARATOR
Intervention: No work
Number of subjects: 187
Study 20487009 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 22
Study 20487009 — intervention group
Group type: EXPERIMENTAL
Intervention: Tokuyama Bond Force
Number of subjects: 22
Study 18721703 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral moxifloxacin 0.5% (250 mug/0.050 mL)
Number of subjects: 47
Study 18721703 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (control)
Number of subjects: 47
Study 16002918 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler (MF‐DPI) 400 microg qd
Number of subjects: 53
Study 16002918 — intervention group
Group type: COMPARATOR
Intervention: HFA‐BDP 200 microg two puffs MDI bid
Number of subjects: 53
Study 16002918 — intervention group
Group type: COMPARATOR
Intervention: CFC‐BDP 400 microg two puffs MDI bid
Number of subjects: 53
Study 12855265 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-chemotherapy (bio-CT)
Number of subjects: 178
Study 12855265 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CT)
Number of subjects: 178
Study 10568212 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEP lecithin gel (1.3% DHEP and 2.4% lecithin)
Number of subjects: 100
Study 10568212 — intervention group
Group type: COMPARATOR
Intervention: DHEP gel (without lecithin)
Number of subjects: 100
Study 10568212 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEP lecithin gel
Number of subjects: 100
Study 10568212 — intervention group
Group type: COMPARATOR
Intervention: DHEP gel
Number of subjects: 100
Study 10568212 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 100
Study 8839597 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition
Number of subjects: 0
Study 8839597 — intervention group
Group type: COMPARATOR
Intervention: Failure to maintain gut function by way of early enteral nutrition
Number of subjects: 0
Study 1826871 — intervention group
Group type: EXPERIMENTAL
Intervention: lovastatin
Number of subjects: 40
Study 1826871 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil
Number of subjects: 40
Study 1826871 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 7144695 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, vincristine, plus prednisone
Number of subjects: 100
Study 7144695 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, doxorubicin, vincristine, plus prednisone
Number of subjects: 100
Study 7144695 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory laparotomy
Number of subjects: 100
Study 7144695 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat lymphangiograms
Number of subjects: 100
Study 7144695 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallium scans
Number of subjects: 100
Study 31335764 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileostomy formation
Number of subjects: 135
Study 31335764 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileostomy takedown
Number of subjects: 135
Study 31023403 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Flow Restricted (BFR) rowing exercise
Number of subjects: 20
Study 28146015 — intervention group
Group type: EXPERIMENTAL
Intervention: Revision surgery for reherniation
Number of subjects: 810
Study 28146015 — intervention group
Group type: COMPARATOR
Intervention: Primary discectomy
Number of subjects: 810
Study 27094721 — intervention group
Group type: EXPERIMENTAL
Intervention: d-cycloserine (DCS)
Number of subjects: 0
Study 27094721 — intervention group
Group type: COMPARATOR
Intervention: modafinil
Number of subjects: 0
Study 27094721 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 24345165 — intervention group
Group type: EXPERIMENTAL
Intervention: D2/D3 dopamine receptor binding measured using [F-18]fallypride
Number of subjects: 0
Study 21972884 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 84
Study 21972884 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 84
Study 21972884 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral position
Number of subjects: 84
Study 19653485 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatialized voices augmented by a visual display of relative talker locations
Number of subjects: 50
Study 19653485 — intervention group
Group type: COMPARATOR
Intervention: Spatialized voices with an audio-only display
Number of subjects: 50
Study 19653485 — intervention group
Group type: COMPARATOR
Intervention: Nonspatialized voices with an audio-only display
Number of subjects: 50
Study 19653485 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatialized voices with large-angle displays
Number of subjects: 50
Study 17726460 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouse TYR DNA vaccine followed by human TYR DNA vaccine (3 injections each, 100, 500, and 1,500 microg DNA/injection, IM every 3 weeks)
Number of subjects: 18
Study 17726460 — intervention group
Group type: EXPERIMENTAL
Intervention: Human TYR DNA vaccine followed by mouse TYR DNA vaccine (3 injections each, 100, 500, and 1,500 microg DNA/injection, IM every 3 weeks)
Number of subjects: 18
Study 17726460 — intervention group
Group type: EXPERIMENTAL
Intervention: Both mouse and human TYR DNA vaccines
Number of subjects: 18
Study 15241748 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based physical therapy (PT) program (prehabilitation)
Number of subjects: 188
Study 15241748 — intervention group
Group type: COMPARATOR
Intervention: Educational control group
Number of subjects: 188
Study 11756645 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural L-glutamine (0.5 g x kg(‐1) x d(‐1))
Number of subjects: 13
Study 10633487 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose haloperidol
Number of subjects: 20
Study 8624062 — intervention group
Group type: EXPERIMENTAL
Intervention: Impedance planimetry
Number of subjects: 24
Study 1478512 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (Group A, n = 19)
Number of subjects: 38
Study 1478512 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate (Group B, n = 19)
Number of subjects: 38
Study 6716120 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower lip perturbations (1 mm and 15 mm loads) during speech gestures
Number of subjects: 0
Study 31029989 — intervention group
Group type: EXPERIMENTAL
Intervention: TLIP block combined with general anesthesia (T group, n=35)
Number of subjects: 72
Study 31029989 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone (C group, n=34)
Number of subjects: 72
Study 29995462 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance-training protocol
Number of subjects: 39
Study 29995462 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength-training protocol
Number of subjects: 39
Study 29995462 — intervention group
Group type: COMPARATOR
Intervention: Control (mild to moderately strenuous bicycle workout)
Number of subjects: 39
Study 27587519 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Controlled Epidural Analgesia (PCEA)
Number of subjects: 222
Study 27587519 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Infiltration Analgesia (LIA)
Number of subjects: 222
Study 25228838 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D group (cholecalciferol 2,000 IU/day + calcium 200 mg/day)
Number of subjects: 81
Study 25228838 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (calcium 200 mg/day)
Number of subjects: 81
Study 21651747 — intervention group
Group type: EXPERIMENTAL
Intervention: Six supervised supplemental exercise sessions
Number of subjects: 118
Study 21651747 — intervention group
Group type: COMPARATOR
Intervention: Three follow-up examinations without exercise (Control)
Number of subjects: 118
Study 20097928 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-strand hamstring autograft (HAM)
Number of subjects: 72
Study 20097928 — intervention group
Group type: COMPARATOR
Intervention: Patellar tendon-bone autograft (PTB)
Number of subjects: 72
Study 20097928 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninvolved knee (HAM)
Number of subjects: 72
Study 20097928 — intervention group
Group type: COMPARATOR
Intervention: Uninvolved knee (PTB)
Number of subjects: 72
Study 17646243 — intervention group
Group type: EXPERIMENTAL
Intervention: Running group (training 3 times/week, 60 min each for 6 months)
Number of subjects: 21
Study 17646243 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling group (training 3 times/week, 90 min each for 6 months)
Number of subjects: 21
Study 17646243 — intervention group
Group type: COMPARATOR
Intervention: Control group (sedentary)
Number of subjects: 21
Study 15980691 — intervention group
Group type: EXPERIMENTAL
Intervention: Coformulated zidovudine/lamivudine/abacavir (group 1)
Number of subjects: 134
Study 15980691 — intervention group
Group type: COMPARATOR
Intervention: Coformulated zidovudine/lamivudine plus nevirapine (group 2)
Number of subjects: 134
Study 15980691 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 134
Study 12627304 — intervention group
Group type: COMPARATOR
Intervention: Strength training only (S)
Number of subjects: 27
Study 12627304 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent strength and endurance training (SE)
Number of subjects: 27
Study 11783186 — intervention group
Group type: EXPERIMENTAL
Intervention: Neiyi 1+ pill (TCM group)
Number of subjects: 45
Study 11783186 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (control group)
Number of subjects: 45
Study 8724034 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination (loviride + lamivudine + zidovudine)
Number of subjects: 20
Study 8724034 — intervention group
Group type: COMPARATOR
Intervention: Double combination (loviride + zidovudine)
Number of subjects: 20
Study 1750290 — intervention group
Group type: EXPERIMENTAL
Intervention: Pump-driven hemofiltration (PDHF)
Number of subjects: 0
Study 1750290 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous hemofiltration
Number of subjects: 0
Study 30010698 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch (RS2) 45 g/d for 12 weeks
Number of subjects: 68
Study 30010698 — intervention group
Group type: COMPARATOR
Intervention: Control group (isocaloric amount of rapidly digestible starch amylopectin)
Number of subjects: 68
Study 27087153 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005 mg/kg cisatracurium
Number of subjects: 90
Study 27087153 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01 mg/kg cisatracurium
Number of subjects: 90
Study 27087153 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02 mg/kg cisatracurium
Number of subjects: 90
Study 27087153 — intervention group
Group type: COMPARATOR
Intervention: Control (no cisatracurium)
Number of subjects: 90
Study 24660759 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD/FDBA (EF)
Number of subjects: 69
Study 24660759 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD/DFDBA (ED)
Number of subjects: 69
Study 24660759 — intervention group
Group type: COMPARATOR
Intervention: EMD alone (E)
Number of subjects: 69